Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Clinical Development

The right questions key to assessing CRO performance, says study team

By Gareth Macdonald , 09-Nov-2011
Last updated the 09-Nov-2011 at 09:17 GMT

The right questions key to assessing CRO performance, says study team
The right questions key to assessing CRO performance, says study team
Loading...

Asking the right questions is key to giving pharmaceutical industry contract managers the information they need to select the best CRO partners according to the team behind a new performance assessment project.

In the second of a series of podcasts Outsourcing-pharma.com spoke with Michael Howley, associate Clinical Professor at Drexel University’s Lebow College of Business, who said the various methods commonly used to measure performance are not always sufficiently detailed.

The first is a fairly general approach were they ask senior pharmaceutical managers something like ‘How satisfied were you with CRO performance?’ and ‘Would you recommend them?’ which are fine questions, but are not detailed enough to give the contract manager that is thinking of hiring that CRO again any insight.”

The second common approach, Howley continued, is often too detailed.

You get question like ‘how many days did it take to recruit subjects for this trial?’ with answers like ‘their average patient recruiting time is 55 days’. Does this mean that the CRO is good at recruiting patients?”

Instead Howley, in partnership with CRO Analytics’ Peter Malamis , is developing an approach that is somewhere between the established methods by asking pharma functional managers how the CRO performed in individual tasks that are important to a successful trial.

We found that the best way to ask these questions is to break them into four stages and in that way we can reach the functional areas managers within the pharmaceutical firms that are actually overseeing [the CROs} and in a legal sense are witnesses to what the CRO actually did.”

So in the patient recruitment phase we would ask ‘how well did the CRO keep you informed of its progress; in the sales and contracting phase ‘how well did they perform in the bid defence?”; later on towards the end of study conduct ‘we ask about the CROs data management practices?’”

This, he continued, enables the gathering of information on discrete tasks which, when bundled together, lead to a more accurate and useful measure of CRO performance.

Howley also urged any Outsourcing-pharma.com readers who are interested in participating in the project during the validation stage to contact him directly at mikehowley@drexel.edu .

Related products

Kemwell CEO says environmental efforts are worth the cost

Kemwell CEO says environmental efforts are worth the cost

Kemwell CEO Agneta Bergvall says drugmakers' efforts to make pharmaceutical manufacturing green are worth...

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Will Downie

Senior VP Global Vusiness Development & Marketing, Catalent

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

Quincy Mattingly

Regional Manager, AlpVision

Cobra Biologics talks recent fill finish acquisition and future growth plans

Cobra Biologics talks recent fill finish acquisition and future growth plans

Philip Ridley-smith

Business Development & Marketing Manager, Cobra Biologics

Catalent says sharing with industry will not dull competetive edge

Catalent says sharing with industry will not dull competetive edge

Kurt Nielsen and Cornell Stamoran

Various, Catalent

Bend Research hunting new partnerships to boost bioavailability offering

Bend Research hunting new partnerships to boost bioavailability offering

David Lyon and Karen Coppens

Various, Bend Research and Dow

Changes to EU clinical trial laws will mean fairer playing field, says Clinipace

Changes to EU clinical trial laws will mean fairer playing field, says Clinipace

Andrea Schiefer

VP of European clinical operations and executive director of pharmacovigilance,...

Home visits = regulatory thumbs up? ResearchNurses.co thinks so

Home visits = regulatory thumbs up? ResearchNurses.co thinks so

Sue Mackay

Research nursing team manager, ResearchNurses.co

Consolidation prevalent in industry, says third largest CMO

Consolidation prevalent in industry, says third largest CMO

Brad Carlson

VP Marketing 7 Sales, Aenova

Catalent commits to ADCs by upping its stake in Redwood

Catalent commits to ADCs by upping its stake in Redwood

Aileen Ruff

Global Strategic Marketing Director, Biologics and Sterile Technologies at Catalent...

Kemwell Talks Expansion and Approvals in India and the US

Kemwell Talks Expansion and Approvals in India and the US

Christian Ahlmark

Director of Corporate Development , Kemwell Biopharma

AMRI Exec Discusses 'New Bar' in FDA Enforcement

Following the completion of remediation efforts to deal with an FDA warning letter, Chris...

Happy holidays from William Reed Business Media!

Happy holidays from William Reed Business Media!

The working year is almost done, time to pause from ‘the business’ and embrace...

Aesica says academic partnerships are key for CMOs

Aesica says academic partnerships are key for CMOs

Alan Raymond

Sales & Marketing Director, Aesica Pharmaceuticals

Wockhardt targets CMO space for diversification

Wockhardt targets CMO space for diversification

Tom Salus

Associate Vice President, Business Development - Contract Services, Wockhardt

Kemwell and Boehringer set to finish biologics plant in India

Kemwell and Boehringer set to finish biologics plant in India

Christian Ahlmark

Director of corporate development , Kemwell

Key Industry Events

 

Access all events listing

Our events, Events from partners...